Showing 1 - 10 results of 10 for search 'Philip Young', query time: 0.05s Refine Results
  1. 1
    Research Access and Discovery in University News Releases: A Case Study

    Research Access and Discovery in University News Releases: A Case Study by Philip Young

    Published 2017-02-01
    Get full text
    Article
  2. 2
    Lifting the fog over ITP

    Lifting the fog over ITP by Philip Young-Ill Choi

    Published 2020-04-01
    Get full text
    Article
  3. 3
    Promoting Universal Knowledge for All: Open Acess Week 2012 at Virginia Tech

    Promoting Universal Knowledge for All: Open Acess Week 2012 at Virginia Tech by Rebecca K. Miller, Kyrille Goldbeck Debose, Nathan Hall, Purdom Lindblad, Allison Scripa, Julie Speer, Philip Young

    Published 2013-08-01
    Get full text
    Article
  4. 4
    Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

    Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors by Philip Young, Omar Elghawy, Joseph Mock, Emmett Wynter, Ryan D. Gentzler, Linda W. Martin, Wendy Novicoff, Richard Hall

    Published 2024-01-01
    Get full text
    Article
  5. 5
    Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

    Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheuma... by Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, Maya H. Buch, Eugeniusz J. Kucharz, Yannick Allanore, Arthur Kavanaugh, Philip Young, Goran Babic

    Published 2019-05-01
    Get full text
    Article
  6. 6
    Characteristics of delirium and its association with sedation and in-hospital mortality in patients with COVID-19 on veno-venous extracorporeal membrane oxygenation

    Characteristics of delirium and its association with sedation and in-hospital mortality in patients with COVID-19 on veno-venous extracorporeal membrane oxygenation by Philip Young-woo Sun, Jonathon Fanning, Anna Peeler, Benjamin Shou, John Lindsley, Giorgio Caturegli, Glenn Whitman, Stephanie Cha, Bo Soo Kim, Sung-Min Cho, Sung-Min Cho, HERALD investigators

    Published 2023-05-01
    Get full text
    Article
  7. 7
    Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.

    Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. by Edgar Turner Overton, Steven J Lawrence, Eva Wagner, Katrin Nopora, Siegfried Rösch, Philip Young, Darja Schmidt, Christian Kreusel, Sonja De Carli, Thomas P Meyer, Heinz Weidenthaler, Nathaly Samy, Paul Chaplin

    Published 2018-01-01
    Get full text
    Article
  8. 8
    A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

    A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Derma... by Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin

    Published 2015-01-01
    Get full text
    Article
  9. 9
    Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.

    Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed... by Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin

    Published 2015-01-01
    Get full text
    Article
  10. 10
    A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

    A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old S... by Richard N Greenberg, Christine M Hay, Jack T Stapleton, Thomas C Marbury, Eva Wagner, Eva Kreitmeir, Siegfried Röesch, Alfred von Krempelhuber, Philip Young, Richard Nichols, Thomas P Meyer, Darja Schmidt, Josef Weigl, Garth Virgin, Nathaly Arndtz-Wiedemann, Paul Chaplin

    Published 2016-01-01
    Get full text
    Article

Search Tools: